Pharmaxis success
May 17, 2014
LISTED Australian
pharmaceutical manufacturer
Pharmaxis has announced
“significant headline results” for the
first stage of an international Phase
III trial of Bronchitrol (inhaled
mannitol) in patients with cystic
fibrosis.
During the trial the lung function
of Bronchitrol treated patients
improved by 7.9% after 18 months.
Pharmaxis ceo Alan Robertson
said the results are “impressive and
of significant clinical importance.
“For cystic fibrosis patients,
consistent loss of lung function,
averaging 1-2% per year, si the
leading cause of death,” he said.
“The improvements now shown
with Bronchitrol treatment over an
18 month period hold out the
promise that Brochitrol can modify
the course of this disease”.
The trial was conducted in 40
centres in the UK, Ireland, Australia
and New Zealand, with the findings
to be presented next month at the
European Cystic Fibrosis
Conference in Valencia, Spain.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 May 14To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 May 14
